Top Nanotechnology Stocks To Watch Today – May 11th

OSI Systems, NVE, Clene, Biodexa Pharmaceuticals, Virpax Pharmaceuticals, and Clene are the seven Nanotechnology stocks to watch today, according to MarketBeat’s stock screener tool. Nanotechnology stocks are equity shares of companies whose core business involves researching, developing or manufacturing materials and devices at the nanometer scale (one billionth of a meter). These firms span industries such as electronics, materials science, healthcare and energy, offering innovations like nanomaterials, nanoelectronics and targeted drug‐delivery systems. Investing in nanotechnology stocks provides exposure to the potential growth of nanoscale technologies but also carries risks tied to research breakthroughs, regulatory hurdles and market adoption. These companies had the highest dollar trading volume of any Nanotechnology stocks within the last several days.

OSI Systems (OSIS)

OSI Systems, Inc. designs and manufactures electronic systems and components. It operates in three segments: Security, Healthcare, and Optoelectronics and Manufacturing. The Security segment offers baggage and parcel inspection, cargo and vehicle inspection, hold baggage and people screening, radiation monitoring, explosive and narcotics trace detection systems, and optical inspection systems under the Rapiscan name.

Shares of OSIS traded up $1.39 during trading hours on Friday, hitting $223.56. The company had a trading volume of 134,062 shares, compared to its average volume of 190,906. OSI Systems has a 12 month low of $129.18 and a 12 month high of $227.34. The firm has a market cap of $3.76 billion, a price-to-earnings ratio of 28.77, a PEG ratio of 1.81 and a beta of 1.28. The business has a fifty day moving average of $195.13 and a 200-day moving average of $182.48. The company has a quick ratio of 1.25, a current ratio of 1.88 and a debt-to-equity ratio of 0.56.

NVE (NVEC)

NVE Corporation develops and sells devices that use spintronics, a nanotechnology that relies on electron spin to acquire, store, and transmit information in the United States and internationally. The company manufactures spintronic products, including sensors and couplers for use in acquiring and transmitting data.

NVEC stock traded up $0.09 during mid-day trading on Friday, hitting $67.64. 12,581 shares of the company were exchanged, compared to its average volume of 22,317. NVE has a 1-year low of $51.50 and a 1-year high of $89.98. The business has a 50 day simple moving average of $61.68 and a 200-day simple moving average of $71.54. The stock has a market capitalization of $327.17 million, a PE ratio of 21.82 and a beta of 1.09.

Clene (CLNN)

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.

NASDAQ:CLNN traded up $0.05 during mid-day trading on Friday, hitting $2.63. 107,625 shares of the stock were exchanged, compared to its average volume of 79,164. The firm’s 50-day simple moving average is $3.37 and its 200 day simple moving average is $4.32. The stock has a market capitalization of $23.63 million, a price-to-earnings ratio of -0.50 and a beta of 0.46. Clene has a fifty-two week low of $2.55 and a fifty-two week high of $9.20.

Biodexa Pharmaceuticals (BDRX)

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.

BDRX stock remained flat at $1.41 during trading hours on Friday. The company’s stock had a trading volume of 34,955 shares, compared to its average volume of 588,895. Biodexa Pharmaceuticals has a 1 year low of $1.14 and a 1 year high of $74.00. The firm has a 50 day moving average price of $1.69 and a 200-day moving average price of $3.57.

Virpax Pharmaceuticals (VRPX)

Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.

Shares of VRPX stock traded down $0.00 on Friday, hitting $0.24. The company’s stock had a trading volume of 1,615 shares, compared to its average volume of 202,265. Virpax Pharmaceuticals has a fifty-two week low of $0.13 and a fifty-two week high of $84.75. The stock’s 50 day moving average is $1.42 and its 200-day moving average is $7.21.

Clene (CLNNW)

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.

NASDAQ:CLNNW traded down $0.00 during trading hours on Friday, reaching $0.03. 10,410 shares of the company were exchanged, compared to its average volume of 11,900. The business has a 50 day moving average of $0.03 and a 200 day moving average of $0.04. Clene has a 1-year low of $0.02 and a 1-year high of $0.08.